Avitide Raises Funds For “On-Demand” Affinity Processing
This article was originally published in Start Up
Executive Summary
In early August, Avitide raised a $7.6 million Series C round that it says will provide sufficient funds for it to commercialize its high-yield process for purifying just about any biological product, a service it will offer to its pharma partners.
You may also be interested in...
VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion
Relay launched with $57m to develop its novel technology platform for drug discovery based on protein motion with an initial focus on therapies for genetically defined cancers.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.